Th1 Immune Response Induction by Biogenic Selenium Nanoparticles in Mice with Breast Cancer: Preliminary Vaccine Model

Authors

  • Ahmad Reza Shahverdi Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Elnaz Faghfouri Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Mehdi Gholami Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Mehdi Mahdavi Department of Immunology, Pasteur Institute of Iran, Tehran, Iran, & Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad Ali Faramarzi Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad Hossein Yazdi Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Zargham Sepehrizadeh Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Zuhair Mohammad Hassan Department of Immunology, Faculty of Medical Sciences, Tarbiat Modaress University, Tehran, Iran
Abstract:

Background: Tumor associated antigens can be viably used to enhance host immune response. Objectives: The immunomodulatory effect of biogenic selenium nanoparticles (SeNPs) was compared between treated and untreated mice with crude antigens of 4T1 cells. Materials and Methods: Female inbred BALB/c mice (60) were injected by cancinogenic 4T1 cells causing breast cancer. After 10 days, all tumor bearing mice were divided into 4 groups. Group 1 was daily provided oral PBS and injected by the same buffer after tumor induction and was considered as control. Group 2 received only 100 mg/day SeNPs as an oral supplement for 30 days. Group 3 was only injected with 4T1 cells crude antigens with nil supplementation of SeNPs.  Group 4 animals were supplemented 100 mg/day SeNPs for 30 days and simultaneously injected with crude antigens of 4T1 cells. All antigens or PBS injections were introduced at 7, 14 and 28 days following tumor induction. Oral PBS and SeNPs supplementation initiated from the first day of tumor induction and continued up to 30 days. During tumor growth, animal weights and survival rates were monitored and at the end of the study the concentrations of different cytokines and DTH responses were measured. Results:  Data clearly showed that the levels of cellular immunomodulatory components (granzyme B, IL-12, IFN-g, and IL-2) significantly increased (P < 0.05) in mice treated with both SeNPs and crude antigens of 4T1 cells in comparison to the other groups. In contrast, the levels of TGF-b in these mice decreased. Conclusions: Although SeNPs showed a noticeable boosting effect for the immune response in mice bearing tumor  exposed to crude antigens of 4T1 cells, further complementary studies seem to be inevitable.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

th1 immune response induction by biogenic selenium nanoparticles in mice with breast cancer: preliminary vaccine model

background: tumor associated antigens can be viably used to enhance host immune response.objectives: the immunomodulatory effect of biogenic selenium nanoparticles (senps) was compared between treated and untreated mice with crude antigens of 4t1 cells.materials and methods: female inbred balb/c mice (60) were injected by cancinogenic 4t1 cells causing breast cancer. after 10 days, all tumor be...

full text

Induction of Immune Response in Animal Model Using Recombinant Anti-NDV Vaccine

Background: Newcastle disease is a major avian disease that causes enormous economic loss in poultry industry. There have been a number of reports on the suitability of plant-based recombinant vaccine against this disease. Fusion (F) and hemagglutinin-neuraminidase (HN) epitopes of the Newcastle disease virus (NDV) represent the major immunogenic sites for development of recomb...

full text

Effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients

Background: Poor response to various vaccines especially hepatitis B is common. The purpose of this study was to evaluate the effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients.Methods: In this randomized clinical trial study, 62 insulin dependent diabetic patients were divided into case and control groups (e...

full text

Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine

Objective(s): Blocking of vascular endothelial growth factor (VEGF) plays a pivotal role in inhibition of metastasis and is a target for development of anti-angiogenic agents. In this study, a peptide-based vaccine was designed and its potential for induction of humoral immune responses, generation of neutralizing antibodies, inhibition of tumor growth and metastasis w...

full text

Evaluation of proliferation and survival of spleen immune cells treated by Deacetylchitin nanoparticles on breast cancer mouse model

Background &&nbsp;Aims: Breast cancer is the most common carcinoma in women and one of the main causes of death in developed and developing countries. Today, compounds with immunolodulator properties can be replaced with routine drugs. One of them is Deacetylchitin. This study aimed to evaluate proliferation and survival of spleen immune cells treated by Deacetylchitin nanoparticles on breast c...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 13  issue 2

pages  1- 9

publication date 2015-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023